Literature DB >> 27438334

Use of Opioid Agonist Therapy for Medicare Patients in 2013.

Anna Lembke1, Jonathan H Chen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27438334      PMCID： PMC5526587          DOI： 10.1001/jamapsychiatry.2016.1390

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN： 2168-622X            Impact factor:   21.596


× No keyword cloud information.
  5 in total

1.  Drug policy and the public good: evidence for effective interventions.

Authors:  John Strang; Thomas Babor; Jonathan Caulkins; Benedikt Fischer; David Foxcroft; Keith Humphreys
Journal:  Lancet       Date:  2012-01-07       Impact factor: 79.321

2.  The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations.

Authors:  Robert Dufour; Ashish V Joshi; Margaret K Pasquale; David Schaaf; Jack Mardekian; George A Andrews; Nick C Patel
Journal:  Pain Pract       Date:  2013-12-01       Impact factor: 3.183

3.  Moving beyond misuse and diversion: the urgent need to consider the role of iatrogenic addiction in the current opioid epidemic.

Authors:  Gillian A Beauchamp; Erin L Winstanley; Shawn A Ryan; Michael S Lyons
Journal:  Am J Public Health       Date:  2014-09-11       Impact factor: 9.308

4.  Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014.

Authors:  Rose A Rudd; Noah Aleshire; Jon E Zibbell; R Matthew Gladden
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-01-01       Impact factor: 17.586

5.  Using natural language processing to identify problem usage of prescription opioids.

Authors:  David S Carrell; David Cronkite; Roy E Palmer; Kathleen Saunders; David E Gross; Elizabeth T Masters; Timothy R Hylan; Michael Von Korff
Journal:  Int J Med Inform       Date:  2015-09-25       Impact factor: 4.046
  5 in total
  12 in total

1.  County-level access to opioid use disorder medications in medicare Part D (2010-2015).

Authors:  Amanda J Abraham; Grace Bagwell Adams; Ashley C Bradford; William D Bradford
Journal:  Health Serv Res       Date:  2019-01-21       Impact factor: 3.402

2.  Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: A descriptive analysis.

Authors:  Aaron Salwan; Nicholas E Hagemeier; Fred Tudiver; KariLynn Dowling-McClay; Kelly N Foster; Jessie Arnold; Arsham Alamian; Robert P Pack
Journal:  J Am Pharm Assoc (2003)       Date:  2020-07-12

Review 3.  Claims-based measures of prescription opioid utilization: A practical guide for researchers.

Authors:  Sara E Heins; Christine Buttorff; Courtney Armstrong; Rosalie Liccardo Pacula
Journal:  Drug Alcohol Depend       Date:  2021-09-22       Impact factor: 4.492

4.  Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

Authors:  Rebecca L Haffajee; Amy S B Bohnert; Pooja A Lagisetty
Journal:  Am J Prev Med       Date:  2018-06       Impact factor: 5.043

5.  Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems.

Authors:  Denise M Boudreau; Gwen Lapham; Eric A Johnson; Jennifer F Bobb; Abigail G Matthews; Jennifer McCormack; David Liu; Cynthia I Campbell; Rebecca C Rossom; Ingrid A Binswanger; Bobbi Jo Yarborough; Julia H Arnsten; Chinazo O Cunningham; Joseph E Glass; Mark T Murphy; Mohammad Zare; Rulin C Hechter; Brian Ahmedani; Jordan M Braciszewski; Viviana E Horigian; José Szapocznik; Jeffrey H Samet; Andrew J Saxon; Robert P Schwartz; Katharine A Bradley
Journal:  J Subst Abuse Treat       Date:  2020-03

6.  Prevalence and treatment of opioid use disorders among primary care patients in six health systems.

Authors:  Gwen Lapham; Denise M Boudreau; Eric A Johnson; Jennifer F Bobb; Abigail G Matthews; Jennifer McCormack; David Liu; Jeffrey H Samet; Andrew J Saxon; Cynthia I Campbell; Joseph E Glass; Rebecca C Rossom; Mark T Murphy; Ingrid A Binswanger; Bobbi Jo H Yarborough; Katharine A Bradley
Journal:  Drug Alcohol Depend       Date:  2019-11-15       Impact factor: 4.492

7.  Buprenorphine Coverage in the Medicare Part D Program for 2007 to 2018.

Authors:  Daniel M Hartung; Kirbee Johnston; Jonah Geddes; Gillian Leichtling; Kelsey C Priest; P Todd Korthuis
Journal:  JAMA       Date:  2019-02-12       Impact factor: 56.272

8.  Outcomes for patients receiving telemedicine-delivered medication-based treatment for Opioid Use Disorder: A retrospective chart review.

Authors:  Eric Weintraub; Aaron D Greenblatt; Joy Chang; Christopher J Welsh; Alexandra P Berthiaume; Shelby R Goodwin; Rachel Arnold; Seth S Himelhoch; Melanie E Bennett; Annabelle M Belcher
Journal:  Heroin Addict Relat Clin Probl       Date:  2021

9.  Effect of opioid prescribing guidelines in primary care.

Authors:  Jonathan H Chen; Jason Hom; Ilana Richman; Steven M Asch; Tanya Podchiyska; Nawal Atwan Johansen
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

10.  Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder.

Authors:  Lewei A Lin; John C Fortney; Amy S B Bohnert; Lara N Coughlin; Lan Zhang; John D Piette
Journal:  J Subst Abuse Treat       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.